Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Opportunities for Easing BTK Inhibitor Switches
Panelists discuss how successful transitions between Bruton tyrosine kinase (BTK) inhibitors require careful management of multiple challenges including optimal timing of the switch, potential washout periods, dose adjustments, patient education about expected adverse effects, and close monitoring during the transition period to maintain treatment efficacy while minimizing complications.
EP: 1.Fixed-Duration Options for CLL
EP: 2.Pirtobrutinib in the BRUIN CLL-321 Study
EP: 3.Incorporating Emerging BTK Therapies Into the CLL Treatment Landscape
EP: 4.Sequencing Considerations in Relapsed/Refractory CLL
EP: 5.Selecting the Optimal BTK Inhibitor in Relapsed/Refractory CLL
EP: 6.Impact of Safety Profiles on BTK Inhibitor Selection in R/R CLL
EP: 7.The Inflation Reduction Act and Cost Considerations for BTK Inhibitors
EP: 8.Switching Between BTK Inhibitors in CLL
EP: 9.Discontinuing Versus Switching BTK Inhibitors for Toxicity
Now Viewing
EP: 10.Opportunities for Easing BTK Inhibitor Switches
Video content above is prompted by the following:
- What challenges do you face when switching between BTK inhibitors, and what strategies can help mitigate these challenges?
- How can oncologists better educate patients about the potential for switching BTK inhibitors to manage toxicities without compromising treatment outcomes?
Related Videos
Related Content
Kansas City Tuberculosis Outbreak Highlights Ongoing Public Health Challenge
February 11th 2025Article
In an interview with The American Journal of Managed Care, Michael A. Bernstein, MD, stressed the need for effective communication and proactive screening to curb the recent tuberculosis (TB) outbreak.
Read More
